tazarotene topical
/ Generic mfg.
- LARVOL DELTA
Home
Next
Prev
1 to 25
Of
284
Go to page
1
2
3
4
5
6
7
8
9
10
11
12
November 28, 2025
Chronic Ulcerative Complications in the Management of Advanced Mycosis Fungoides with Large Cell Transformation
(ISDS 2025)
- "Though initially treated with localized radiation, methotrexate, bexarotene, and narrowband UVB phototherapy, funding limitations disrupted therapy continuity...Management included total skin electron beam therapy, reintroduction of oral bexarotene (750 mg daily), and topical Triamcinolone, later switched to tazarotene cream...At follow-up, the patient reported significant improvement in skin lesions leg ulcers with partial disease response and no lymphadenopathy or hepatosplenomegaly despite persistent ulceration. This case highlights the challenges of advanced mycosis fungoides with large cell transformation and ulcerations, where the relapsing course of cutaneous T-cell lymphoma necessitates multidisciplinary care, and the leading infectious complication is Staphylococcus aureus-driven cellulitis and bacteremia due to skin barrier disruption."
Metastases • Cutaneous T-cell Lymphoma • Dermatology • Hematological Malignancies • Infectious Disease • Lymphoma • Mycosis Fungoides • Oncology • T Cell Non-Hodgkin Lymphoma • Ulcerative Colitis
November 12, 2025
Coating Janus Nanoparticles with Immunoregulatory Protein Embedded Membrane for Enhanced Anti-Inflammatory and Sonodynamic Therapy of Psoriasis.
(PubMed, Adv Healthc Mater)
- "The encapsulated core is designed as Janus nanoparticles (mSiO2&rPMO) for co-delivery of hydrophilic 5-aminolevulinic acid (5-ALA) and hydrophobic tazarotene, facilitating synergistic sonodynamic therapy (SDT) and anti-inflammatory effects...Notably, CNPs outperformed non-membrane counterparts in both cellular and animal models, highlighting the anti-psoriatic amplification conferred by the engineered membrane. Overall, this research presents a novel therapeutic strategy for psoriasis management using engineered membrane-coated mesoporous Janus nanoparticles to target keratinocyte proliferation and T cell activation."
Journal • Dermatology • Immunology • Inflammation • Psoriasis • RARG
October 31, 2025
A Rare Dermatologic Condition: Insights from Three Cases of Circumscribed Acral Hypokeratosis.
(PubMed, Clin Dermatol)
- "Therapeutic responses were varied to topical calcipotriene, tazarotene, antifungal agents, and fractional laser therapy, highlighting the absence of standardized treatment guidelines...Due to its benign yet chronic and refractory nature, accurate histopathologic diagnosis is crucial to facilitate appropriate management and surveillance for such rare potential complications as squamous dysplasia. This series underscores the importance of recognizing CAH's distinct clinicopathologic entity to guide effective clinical management."
Journal • Aesthetic Medicine • Dermatitis • Dermatology • Human Papillomavirus Infection • Immunology • Infectious Disease • Inflammation • Mood Disorders • Psoriasis
October 02, 2025
Effects of AI-Powered Embodied Avatars on Communication Quality and Social Connection in Asynchronous Virtual Meetings.
(PubMed, IEEE Trans Vis Comput Graph)
- "Results showed that Avagents enhance the asynchronous communication experience by increasing social presence, sense of belonging, emotional intimacy, and other user perceptions. We discuss the findings and their implications for designing effective AI-driven asynchronous communication tools in VR/AR environments."
Journal • Cognitive Disorders
July 23, 2025
comparative efficacy of topical methotrexate and topical tazarotene in psoriasis vulgaris
(EADV 2025)
- "Topical methotrexate and topical tazarotene are mildly effective in treatment of psoriasis vulgaris with comparable efficacy. Adverse effects of both topical methotrexate and topical tazarotene were mild and well tolerable. However their use as monotherapy cannot be advocated from the study findings."
Clinical • Dermatology • Immunology • Pruritus • Psoriasis
July 23, 2025
Delphi Consensus Recommendations of the IADVL Special Interest Group on Mild to Moderate Psoriasis: Role of Topical Therapies and Phototherapy in Psoriasis Care
(EADV 2025)
- " The panel established consensus on the role of various topical agents including corticosteroids, vitamin D analogues, calcineurin inhibitors, coal tar, anthralin, tazarotene, and combination regimens... This consensus document provides practical, evidence-informed recommendations for the non-systemic management of mild to moderate psoriasis in India. By integrating clinical evidence with regional context and expert opinion, these guidelines aim to optimize psoriasis care and standardize therapeutic approaches among Indian dermatologists."
Dermatology • Immunology • Psoriasis
July 23, 2025
Eruptive Vellus Hair Cysts: ''A Rare Clinical and Histopathological Challenge''
(EADV 2025)
- "(Figures) The patient was prescribed topical tazarotene 0.1% and scheduled for follow-up... EVHC should be considered in the differential diagnosis of multiple cystic or comedone-like papules in young individuals. Histological examination is essential for definitive diagnosis. Recognition of this entity can guide appropriate, conservative treatment and avoid unnecessary interventions."
Clinical • Infectious Disease • Inflammation • Pruritus • KRT17
July 16, 2025
Comparison of the efficacy and safety of narrowband UVB alone versus narrowband UVB combined with topical tazarotene in the treatment of psoriasis
(EADV 2025)
- No abstract available
Clinical • Dermatology • Immunology • Psoriasis
August 29, 2025
Preclinical assessment of a CYP26B1 inhibitor for treating acne and keratinization disorders.
(ESDR 2025)
- "Local tolerance was assessed against marketed retinoids Trifarotene and Tazarotene in Göttingen minipigs over three weeks, and comedolytic activity was evaluated in rhino mice. Pregnant rats treated with the dual CYP26A1/B1 inhibitor showed complete early resorptions and no live fetuses. These results suggest CYP26B1 inhibitors are promising for treating keratinization disorders and acne with fewer retinoid-induced side effects."
Preclinical • Acne Vulgaris • Atopic Dermatitis • Immunology • Vitiligo • CYP26A1
August 10, 2025
Design, Optimization and In Vivo Evaluation of Tazarotene Loaded Emulgel Formulation for the Treatment of Acne.
(PubMed, J Drug Target)
- "Anti-acne efficacy was evaluated using a Propionibacterium acnes-induced murine model, where the optimized emulgel significantly reduced acne lesion size from 4.5 mm to 0 mm, compared to a marketed gel, which reduced lesions from 4.6 mm to 2.3 mm. These results highlight the tazarotene-loaded emulgel as a promising and safe topical treatment for acne, offering superior efficacy over marketed formulations."
Journal • Preclinical • Acne Vulgaris • Dermatology
August 07, 2025
Resolving Hyperkeratotic Psoriasis: Mechanisms of Action and Additive Effects of Fixed-Combination Halobetasol Propionate and Tazarotene.
(PubMed, J Drugs Dermatol)
- "This review suggests that HP/TAZ is a valuable option for the topical treatment of severe hyperkeratotic plaques through its additive mechanisms targeting inflammation and keratinocyte regulation."
Journal • Review • Dermatology • Immunology • Oncology • Psoriasis • IL17A • TNFA
August 07, 2025
Halobetasol Propionate/Tazarotene Lotion for Scalp Psoriasis: Efficacy in Itch Reduction, Disease Clearance, and Hair Appearance.
(PubMed, J Drugs Dermatol)
- "No adverse events were reported. HP/TAZ is an efficacious treatment for scalp psoriasis, and reductions in psoriatic disease and itch may reduce scratching, leading to improvements in hair and scalp health."
Clinical • Journal • Alopecia • Dermatology • Immunology • Psoriasis
July 29, 2025
Tazarotene-Induced Gene 3 (TIG3) Induces Apoptosis in Melanoma Cells Through the Modulation of Inhibitors of Apoptosis Proteins.
(PubMed, Biomedicines)
- "Supplementation with cIAP-1, HTRA2, or Livin partially reversed TIG3-induced Caspase-3 expression and cell death. Our findings suggest that TIG3 may contribute to the anti-melanoma effects of retinoic acid, with IAP family proteins playing a key role in the TIG3-mediated regulation of melanoma cell survival."
Journal • Melanoma • Oncology • Solid Tumor • CASP3 • CLSPN, • CLU
July 25, 2025
Comparative efficacy of topical interventions for facial photoaging: a network meta-analysis.
(PubMed, Sci Rep)
- "Bayesian network meta-analysis showed isotretinoin, retinol, and tretinoin significantly improved fine wrinkles, with isotretinoin ranked highest. Tazarotene was most effective for coarse wrinkles, while glycolic acid reduced roughness...However, limitations included limited racial diversity, potential commercial bias, and variability in dermatological assessments. These findings provide evidence-based guidance for clinical decision-making in anti-photoaging therapy."
Clinical • Journal • Retrospective data • Review
July 23, 2025
Exploring Potential Therapeutic Applications of Tazarotene: Gene Regulation Mechanisms and Effects on Melanoma Cell Growth.
(PubMed, Curr Issues Mol Biol)
- "Additionally, we assess the advantages and challenges of using tazarotene as a topical treatment and explore its future clinical applications. These studies contribute to a wider understanding of tazarotene's antitumor mechanisms, providing a solid theoretical foundation for its potential as a therapeutic option for melanoma in situ."
Journal • Review • Acne Vulgaris • Dermatology • Immunology • Melanoma • Oncology • Psoriasis • Solid Tumor
July 04, 2025
A Novel Role for Tazarotene-induced Gene 1 in Suppressing Melanoma Growth - Schlafen 11.
(PubMed, Front Biosci (Landmark Ed))
- No abstract available
Journal • Melanoma • Oncology • Solid Tumor
June 06, 2025
Clinical research of Tazarotene Betasone Cream in the Treatment of Chronic Eczema
(ChiCTR)
- P4 | N=150 | Recruiting | Sponsor: Shenzhen University General Hospital; Shenzhen University General Hospital
New P4 trial • Atopic Dermatitis • Dermatology • Immunology
June 06, 2025
Efficacy and safety of tazarotene betasone cream in the treatment of inflammatory lichen/keratotic dermatosis: a randomized, controlled study
(ChiCTR)
- P4 | N=420 | Not yet recruiting | Sponsor: Xi'an Jiaotong University Second Affiliated Hospital; Xi'an Jiaotong University Second Affiliated Hospital
New P4 trial • Amyloidosis • Atopic Dermatitis • Dermatitis • Dermatology • Immunology
March 27, 2025
Single Cell Fixed RNA Profiling reveals Hepatocytes (Cyp2e1+Cyp1a2+Tnx1+) drives liver fibrosis regression via retinoic acid receptor responder 2
(APASL 2025)
- "Pharmacological induction of RARRES1/2 expression in human hepatic stellate cells (HHSteCs) using all-trans retinoic acid, adapalene, bexarotene, or tazarotene dose-dependently suppressed HSC activation by downregulating COL1A1 and α-SMA expression. This study uncovered previously unrecognized molecular and cellular mechanisms of hepatocytes in liver fibrosis regression, identifying RARRES2 as a potential biomarker and therapeutic target for antifibrotic treatment. Table and Figure:Figure 1. Figure 2."
Fibrosis • Hepatology • Immunology • Liver Cirrhosis • COL1A1 • CYP1A2 • CYP2E1 • RARRES1 • RARRES2 • TGFB1
March 24, 2025
Combined cryotherapy and topical imiquimod, 5-fluorouracil, and tazarotene effectively treats locally advanced basal cell carcinoma and is associated with nearby nodular basal carcinoma regression.
(PubMed, JAAD Case Rep)
- No abstract available
Journal • Basal Cell Carcinoma • Non-melanoma Skin Cancer • Oncology
February 26, 2025
A Retrospective Analysis of Adherence to Acne Treatment Guidelines
(AAD 2025)
- "Topical treatments (adapalene, benzoyl peroxide, tazarotene, tretinoin, trifarotene) tried within 12 months prior to antibiotics were included. This study provides an automated approach to assess adherence to acne treatment guidelines. Next steps involve educating providers on these guidelines and assessing changes in adherence."
Adherence • Retrospective data • Acne Vulgaris • Dermatology • Dermatopathology • Hidradenitis Suppurativa • Immunology • Infectious Disease • Malaria • Pneumonia • Respiratory Diseases • Rosacea
February 22, 2025
Rural-urban disparities in the use of FDA-approved steroid-sparing topical medications for inflammatory dermatologic conditions: A DataDerm study
(AAD 2025)
- " Compared to rural patients, urban patients were more likely to be prescribed 3 of 6 topicals queried: crisaborole (OR 1.46, p<0.001), roflumilast (OR 11603130, p<0.001), and tacrolimus (OR 1.57, p<0.001). While odds ratios for pimecrolimus, tapinarof, and tazarotene also exceeded 1.0, no statistically significant differences were observed for these medications. There is an evident disparity in prescribing patterns for steroid-sparing topical medications between urban and rural populations, with the former being less likely to incur steroid-related adverse effects such as dermal atrophy. This could be attributable to differences in the concentration of dermatologists between these areas (4), with rural patients encountering significantly more obstacles in accessing dermatologic care."
Atopic Dermatitis • Dermatitis • Dermatology • Hidradenitis Suppurativa • Immunology • Inflammation • Psoriasis
February 22, 2025
Linear Darier Disease Treated with Ruxolitinib: A Case Report and Review of the Literature
(AAD 2025)
- "A treatment trial of topical ruxolitinib, ammonium lactate, and tazarotene was initiated. This case report presents the first documented use of ruxolitinib for linear Darier disease, demonstrating its potential as an effective treatment option for managing this rare genodermatosis. Further research is needed to establish ruxolitinib's role in the treatment of Darier disease."
Case report • Clinical • Review • Dermatology • Oncology • Pruritus
February 22, 2025
Cleanse, Treat, Moisturize, Protect (CTMP®) regimen: Enhancing skin quality and treatment outcomes in acne and sensitive skin
(AAD 2025)
- "Retinoids, such as adapalene, tretinoin, tazarotene, and trifarotene, are considered fundamental topical acne treatments as they target multiple disease aspects (5), and are frequently studied with regimens of cleansers, moisturizers, and protection (6-11). The review also found that combined drug treatments (e.g., topical trifarotene or other retinoids) and corrective procedures (e.g., fillers) may provide optimal treatment outcomes and satisfaction for some patients (21). Overall, the narrative review found that CTMP® may improve adherence, treatment outcomes, patient satisfaction, and overall skin quality in patients with acne and/or sensitive skin."
Clinical • Acne Vulgaris
March 03, 2025
Comparison of Efficacy of the Combination of Topical Tazarotene Gel and Oral Fluconazole Versus Oral Fluconazole Monotherapy in the Treatment of Onychomycosis.
(PubMed, Cureus)
- "The efficacy of oral weekly fluconazole combined with daily topical tazarotene 0.1% gel is significantly higher than that of weekly fluconazole monotherapy in the treatment of OM."
Journal • Monotherapy • Dermatology • Infectious Disease
1 to 25
Of
284
Go to page
1
2
3
4
5
6
7
8
9
10
11
12